Tiziana Life Sciences is a biotechnology company that is focused on the discovery and development of molecules and related diagnostics. Co.'s main product candidate in immunology is Foralumab (TZLS-401), which is a human anti-CD3 monoclonal antibody in clinical development. In addition, Co. is accelerating development of another human monoclonal antibody anti-IL6R (TZLS-501) to treat acute inflammation resulting from infection with viral agents such as Coronaviruses. Co.'s lead product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule spectrum inhibitor of cyclin-dependent kinases and Src family kinase. The TLSA stock yearly return is shown above.
The yearly return on the TLSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TLSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|